Powikłania radioterapii u chorych na pierwotnego inwazyjnego raka pochwy by Blecharz, Paweł et al.
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e Nr 03/2013206
P R A C E  O R Y G I N A L N E
  ginekologia
    
Ginekol Pol. 2013, 84, 206-210
 
Radiation therapy complications in patients 
with primary invasive vaginal carcinoma
Powikłania radioterapii u chorych na pierwotnego inwazyjnego 
raka pochwy 
 
Paweł	Blecharz1,	Marian	Reinfuss2,	Jerzy	Jakubowicz2,	Piotr	Skotnicki3, 
Elżbieta	Łuczyńska4,	Maciej	Bodzek5,	Krzysztof	Urbański	1
1 Department of Gynecologic Oncology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland
2 Department of Radiation Oncology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland 
3 Department of Surgical Oncology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland
4 Department of Diagnostic Imaging, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland
5 Department of Obstetrisc and Gynecology, L.Rydygier Memorial Hospital, Krakow. Poland
 Abstract    
Objectives: The aim of the study was to estimate acute and late complications of radiation therapy in primary 
invasive vaginal carcinoma (PIVC) patients. 
Material and methods: The analysis was performed for the group of 152 PIVC patients given radical radiotherapy 
in the Krakow Branch of Centre of Oncology during the 1967–2005 period. Twenty five (16.5%) patients in I stage 
with primary tumour of the thickness not larger than 0.5 cm were treated with intracavitary brachytherapy alone; 
for 120 (78.9%) patients (stages I – IVA) intracavitary brachytherapy was combined with external radiation therapy; 
and 7 (4.6%) patients in stage IVA were given only external radiotherapy. In total, 145 (95.4%) patients were treated 
with intracavitary LDR brachyterapy by means of Ra-226 or afterloaded Cs-137 sources, and 127 (83.5%) received 
external radiation therapy using Co-60 and linac 10MV or 6MV photon beams.
Results: Early radiotherapy tolerance was good in the investigated group; 146 (96.1%) patients completed full 
planned radiation therapy treatment. Late complications of radiation therapy were observed in 21 (13.8%) patients: 
3 (2%) patients reported mild complications, 12 (7.9%) moderate complications, and 6 (3.9%) severe complica-
tions. Severe complications of radiation therapy in the investigated group included: recto-vaginal fistula (5 patients) 
and vesico-vaginal fistula (1 patient). None of the patients in the group died of radiation therapy complications.
Conclusions: Early tolerance of radiotherapy in PIVC patients is generally good. Late radiation therapy com-
plications, particularly the severe, are rare and can be efficiently managed with conservative therapy or surgical 
treatment.
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Introduction
Radiation	therapy	is	the	treatment	of	choice	for	most	of	the	
primary	invasive	vaginal	carcinoma	(PIVC)	patients	[1-10].	Of	
the	essential	importance	is	intravaginal	treatment.	The	source	of	
ionizing	radiation	in	intracavitary	brachytherapy	is	radium	(Ra-
226)	(rarely	used	nowadays)	and	afterloaded	caesium	(Cs-137)	
or	 iridium	 (Ir-192);	 interstitial	 brachytherapy	 is	 performed	 by	
means	 of	 permanent	 implants	 of	 radioactive	 gold	 (Au-198)	 or	
iodine	 (I-125),	 and	 temporary	 implants	 containing	 radioactive	
iridium	 (Ir-192).	 Both	 brachytherapy	modalities	 are	 combined	
for	 part	 of	 the	 patients.	 In	 cases	 of	 vaginal	 vault	 involvement	
additional	 intrauterine	 applicator	 is	 used	 [6,	 8-16].	 Generally,	
PIVC	 patients	 are	 advised	 low-dose	 rate	 (LDR,	 0,4-2Gy/h)	
treatment	and	rarely	medium-dose	rate	treatment	(MDR,	2Gy	–	
12Gy/h).	In	recent	years,	a	growing	number	of	institutions	uses	
iridium	 sources	 of	 a	 high-dose	 rate	 (HDR,	 over	 12Gy/h).	 For	
most	of	the	patients	intravaginal	brachytherapy	is	supplemented	
with	external	radiation	therapy	[6,	16-19].	Selected	non-advanced	
PIVC	patients	with	 small	 (up	 to	0.5	 cm)	 superficial	neoplastic	
lesions	may	be	treated	with	brachytherapy	alone	[6,	10,	11,	16,	
18,	19].	
Objectives
The	 aim	 of	 the	 study	 was	 the	 analysis	 of	 acute	 and	 late	
complications	of	 radiation	 therapy	 in	PIVC	patients.	There	are	
many	controversies	on	the	subject	in	the	literature	and	their	main	
reasons	include	rare	occurrence	of	PIVC,	differences	in	clinical	
profile	and	radiotherapy	techniques	advised	in	analyzed	groups	
of	 patients,	 diverse	 type	 and	 severity	 assessment	 scales	 of	 the	
complications	[6,	15,	17,	19-25].	
Material and methods
The	detailed	analysis	was	performed	 for	 the	group	of	152	
PIVC	patients	given	radical	radiotherapy	in	the	Krakow	Branch	
of	Centre	of	Oncology	 (COOK)	during	 the	1967–2005	period.	
Demographic,	 clinical	 and	 histopathological	 characteristics	 of	
the	 investigated	 group	 have	 been	 presented	 in	 detail	 in	 earlier	
work,	“Prognostic	factors	for	vaginal	carcinoma	patients”.	
Radiotherapy modalities
Table	 I	 presents	 radiotherapy	 modalities	 applied	 in	 the	
investigated	 group	 of	 patients	 in	 relation	 to	 FIGO	 stage	 of	
neoplastic	disease.	
Hundred	and	forty	five	(95.4%)	patients	were	 treated	with	
intracavitary	 LDR	 brachytherapy	 using	 radium-226	 (manual	
loading)	 or	 cesium-137	 (Selectron	 LDR/MDR	 afterloader)	
sources,	among	which	131	(90.3%)	patients	were	given	a	single-
fraction	 treatment	 and	 14	 (9.7%)	 a	 2-fraction	 course	 with	 a	
3-week-interval.	For	25	(16.5%)	patients	of	the	investigated	group	
intracavitary	 brachytherapy	 was	 the	 only	 treatment	 advised;	
 Streszczenie  
Cel pracy: Celem pracy była ocena wczesnych i późnych powikłań radioterapii chorych na pierwotnego 
inwazyjnego raka pochwy (PIVC). 
Materiał i metody: Przedmiotem analizy była grupa 152 chorych na PIVC napromienianych radykalnie 
w krakowskim Oddziale Centrum Onkologii w latach 1967-2005. U 25 (16,5%) chorych na PIVC w I0 zaawansowania, 
ze zmianą pierwotną nieprzekraczającą 0,5cm grubości przeprowadzono wyłącznie brachyterapię dojamową, 
u 120 (78,9%) chorych (I0- IVA0) brachyterapię dojamową skojarzoną z  teleradioterapią, a u 7 (4,6%) chorych 
w IVA0 zaawansowania wyłącznie teleradioterapię. W sumie, u 145 (95,4%) chorych zastosowano brachyterapię 
dojamową LDR radem-226 lub cezem-137, a  u  127 (83,5%) teleradioterapię w  warunkach telegammaterapii 
kobaltem-60 lub promieniowania X o energii 10MeV lub 6MeV z akceleratorów liniowych.
Wyniki: Bezpośrednia tolerancja radioterapii w badanej grupie chorych była dobra; pełną zaplanowaną radioterapię 
przeprowadzono u 146 (96,1%) chorych. Późne powikłania napromieniania stwierdzono u 21 (13,8%) chorych: u 3 
(2%) były to powikłania o średnim nasileniu, u 12 (7,9%) znacznym nasileniu i u 6 (3,9%) – o bardzo ciężkim nasileniu. 
Ciężkie powikłania radioterapii w badanej grupie chorych to: przetoka pochwowo-odbytnicza (5 chorych) i przetoka 
pochwowo-pęcherzowa (1 chora). Żadna chora z badanej grupy nie zmarła z powodu powikłań radioterapii.
Wnioski: Bezpośrednia tolerancja radioterapii chorych na PIVC jest zasadniczo dobra. Późne powikłania 
radioterapii, szczególnie ciężkie są rzadkie i mogą być skutecznie leczone zachowawczo lub operacyjnie. 
 Słowa kluczowe: radioterapia / rak pochwy / powikłania /
Table I. Radiotherapy modalities applied in the group of 152 PIVC patients. 
FIGO  
stage  
of PIVC
Radiotherapy modality
Numer of patients
No. %
I0
intracavitary brachytherapy
intracavitary brachytherapy  
+ external radiotherapy 
25
14
16.5
 9.2
II0 and III0 intracavitary brachytherapy  + external radiotherapy 91 59.8
IVA0
intracavitary brachytherapy  
+ external radiotherapy
external radiotherapy alone
15
 7
9.9
4.6
Total 152 100.0
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all	of	 them	had	stage	 I0	PIVC	and	 the	primary	 tumour	did	not	
exceed	0.5	cm	in	thickness	and	2	cm	in	its	largest	dimension.	The	
treatment	was	performed	using	vaginal	colpostat	(2	applicators	
along	vagina	axis	with	2	additional	dome	applicators	in	cases	of	
upper	vagina	involvement).	Total	radiation	dose	to	primary	tumor	
calculated	 at	 0.5cm	 distance	 from	 vaginal	 mucosa	 was	 65-70	
Gy;	vaginal	mucosa	received	dose	of	95-100	Gy.	Remaining	14	
(9.2%)	patients	in	stage	I0	PIVC	with	primary	tumour	exceeding	
0.5	 cm	 thickness	 were	 additionally	 given	 external	 radiation	
therapy	involving	whole	pelvis	minor	irradiation	to	50	Gy	in	25	
fractions	within	5-week-period.
All	of	the	91	patients	with	stage	II0	and	III0	PIVC	were	treated	
with	the	combination	of	intracavitary	brachytherapy	and	external	
radiotherapy.	 Intracavitary	 brachytherapy	 dose	 to	 infiltration	
base	was	65-70Gy.	Dose	to	Manchester	A	points	varied	from	44	
to	62Gy	(mean	value	of	52Gy)	with	the	overall	irradiation	time	of	
72	up	to	132	hours,	most	commonly	within	96-120	hours	range.	
Rectal	mucosa	dose	received	due	to	intracavitary	brachytherapy	
was	 31	 to	 56Gy;	 for	most	 of	 the	 patients	 it	 stayed	within	 35-
40Gy	range.	If	the	primary	tumour	was	located	in	the	upper	third	
of	vagina,	vaginal	colpostat	was	used	together	with	intrauterine	
applicator.
Fifteen	(9.9%)	of	22	IVA0	stage	PIVC	patients	were	advised	
intracavitary	 brachytherapy	 (as	 in	 case	 of	 I0	 and	 III0	 stage)	 in	
combination	with	 external	 radiotherapy;	 7	 (4.6%)	 patients,	 for	
whom	 it	was	 technically	 not	 possible	 to	 perform	 intracavitary	
brachytherapy	due	to	the	extent	of	neoplastic	disease	in	vagina,	
were	treated	with	external	radiation	therapy	alone.
In	total,	127	(83.5%)	patients	received	external	radiotherapy	
treatment:	58	(45.7%)	were	irradiated	with	Co-60	beams	and	the	
remaining	69	(54.3%)	with	10MV	or	6MV	linac	photon	beams.	
Patients	 were	 treated	 with	 four	 external	 beams:	 anterior	
field,	posterior	field	and	two	opposite	lateral	fields	(so	called	box	
technique).	
AP-PA	 fields	 covered	 the	 area	 from	 the	 lower	 edge	 of	
obturator	 foramens	 up	 to	 L4-L5	 junction	 level	 with	 lateral	
boundaries	extending	1-1.5cm	sideways	outside	the	pelvic	brim.	
Lateral	fields	were	limited	in	the	anterior	direction	by	the	pubic	
symphysis.	
Entry	field	size	was	15x15cm	to	15x18cm	for	AP-PA	fields,	
and	 15x8cm	 to	 15x10cm	 for	 lateral	 fields.	 Pelvis	 minor	 area	
determined	 this	way	was	 irradiated	with	 daily	 dose	 of	 2Gy	 to	
total	dose	of	50Gy	in	25	fractions	within	5-week-period.	
Tumour	 dose	was	 calculated	 at	 the	 intersection	 of	AP-PA	
and	 lateral	 fields	 axes.	 It	was	 assumed	 that	 all	 the	 beams	 had	
equal	dose	contribution	of	12.5Gy.	All	the	fields	were	irradiated	
during	one	 session	 a	 day.	Patients	with	 primary	 tumour	 in	 the	
lower	third	of	vagina	were	advised	elective	inguinal	irradiation.	
Four	 patients	 with	 histopathology	 confirmed	 PIVC	
metastasis	 in	 inguinal	 lymph	 nodes	were	 given	 additional	 15-
20Gy	dose	(“boost”)	to	that	area	using	smaller	fields	of	15MeV	
electron	 beams.	 Seven	 IVA0	 stage	 PIVC	 patients	 treated	 with	
external	 radiotherapy	 alone	 were	 given	 15-20Gy	 boost	 using	
“shrinking-field	technique”	up	to	total	dose	of	65-70Gy.	
Of	 the	 152	 patients	 in	 the	 investigated	 group,	 70	 (46.1%)	
had	5-year	disease-free	survival	(DFS),	74	(48.7%)	died	of	PIVC	
during	the	5-year	follow-up	period,	and	8	(5.2%)	died	of	other	
cause.	Detailed	analysis	of	treatment	results	has	been	presented	in	
earlier	work,	“Prognostic	factors	for	vaginal	carcinoma	patients”.	
Treatment course and complications
All	 the	 patients	 of	 the	 investigated	 group	 developed	
symptoms	 of	 postradiation	 reaction	 with	 69	 (45.4%)	 cases	 of	
considerable	 severity,	 mainly	 including	 loose	 stool,	 diarrhoea,	
abdominal	 pain,	 pollakiuria,	 difficulty	 and	 pain	 during	
micturition,	 purulent	 or	 bloody-and-mucoid	 vaginal	 discharge.	
Advised	 treatment	 involved	 diet	 control,	 administration	 of	
antidiarrhoeic	drugs,	analgesics	and	antibacterial	drugs,	vagina	
irrigation,	 etc.	 In	 definite	majority	 of	 the	 patients	 (94.7%)	 the	
symptoms	subsided	within	2-3	months	 from	the	completion	of	
radiotherapy;	in	several	cases	it	lasted	a	little	longer. 
Table	II	presents	the	course	of	radiotherapy	treatment	in	the	
investigated	group	of	patients.
Data	 presented	 in	 Table	 II	 suggest	 that	 the	 radiotherapy	
tolerance	in	the	investigated	group	of	patients	was	good.	Hundred	
forty	six	(96.1%)	patients	completed	full	planned	radiotherapy.	
Six	(3.9%)	patients	completed	planned	brachytherapy,	but	were	
not	given	full	planned	external	radiotherapy	dose	due	to	condition	
deterioration	(2	patients),	exacerbation	of	accompanying	disease	
symptoms	 (3	 patients)	 and	 further	 radiotherapy	 refusal	 (1	
patient).	 In	 all	 these	 cases	patients	 received	 at	 least	 2/3	of	 the	
planned	external	radiotherapy	dose.
Late	 complications	 of	 radiation	 therapy	were	 observed	 in	
21	(13.8%)	patients	of	the	investigated	group.	Table	III	presents	
reported	complications	as	defined	by	the	glossary	by	Chassagne	
et al.	published	in	1993	[20].	
Late	 radiotherapy	 complications	 in	 the	 investigated	 group	
included	G1	complications	observed	 in	3	 (2%)	patients,	G2	 in	
12	(7.9%)	patients,	and	G3	in	6	(3.9%)	patients.	There	were	no	
G4	complications	in	the	group	so	that	none	of	the	patients	died	
directly	of	radiotherapy	complications.
Eleven	 patients	 had	 rectal	 complications	 in	 the	 form	 of	
recto-vaginal	fistula	(G3a)	–	5	patients,	chronic	rectal	bleeding	
periodically	 requiring	 hospitalization	 and	 blood	 transfusion	
(G2a)	 –	 3	 patients,	 and	 pain	 and	 tenesmus	 associated	 with	
necrotic	rectal	ulceration	(G2b)	–	3	patients.
Bladder	complications	were	observed	in	5	patients:	vesico-
vaginal	fistula	(G3d)	in	1	patient,	hematuria	periodically	requiring	
Table II. Course of radiotherapy treatment of 152 PIVC patients.
Radiotherapy treatment 
course
Numer of 
patients
%
Full planned radiotherapy 
treatment completed without 
interruptions
142  93.5
Full planned radiotherapy 
completed with an interruption 
during the treatment
  4 2.6
Planned brachytherapy 
completed without completing 
external radiotherapy
 6 3.9
Total 152 100.0
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hospitalization	 and	 blood	 transfusion	 as	 well	 as	 intensive	
antibacterial	 treatment	 (G3a)	 in	 3	 patients,	 and	 occasional	
incontinence	(G1c)	in	1	patient.	
Vagina	 complications	 observed	 in	 5	 patients	 included	
vaginal	narrowing	and	shortening	to	more	than	half	the	original	
dimensions	(G2a)	–	2	cases,	symptomatic	vulval	fibrosis	(G2c)	–	
1	case,	and	vaginal	narrowing	and	shortening	to	less	than	half	the	
original	dimensions	(G1b)	–	2	cases.
Late	radiotherapy	complications	occurred	in	the	investigated	
group	of	patients	7	to	34	months	after	the	treatment	completion	
with	2/3	of	the	cases	manifesting	after	10	to	13	months.	
All	 the	 G1	 and	 G2	 complications	 were	 managed	 with	
conservative	therapy.	Chronic	rectal	bleeding	and	hematuria	were	
treated	with	blood	transfusion,	bladder	infusions	and	enemas	of	
agents	controlling	bleeding	and	accelerating	ulceration	healing,	
antibiotic	 treatment,	 analgesic	 and	 anti-inflammatory	 drugs;	
tenesmus	 patients	 were	 advised	 dietetic	 and	 antidiarrhoeic	
treatment.	 Inflammatory	 condition	 in	 vagina	 was	 reduced	
by	 general	 anti-inflammatory	 treatment	 and	 regular	 vagina	
irrigation.	Attempts	were	made	to	prevent	vaginal	narrowing	by	
regular	vagina	dilatation	as	well	as	local	application	of	oestrogen	
creams	or	pentoxifylline	with	vitamin	E.	In	most	of	the	cases	the	
conservative	treatment	proved	to	be	effective	and	the	symptoms	
subsided	within	few	months	or	were	considerably	reduced	(e.g.	
vagina	narrowing).	
Six	patients	 in	 the	group	developed	fistulas	 (5	cases	of	3a	
grade	recto-vaginal	fistula	and	1	case	of	3d	grade	vesico-vaginal	
fistula).	Three	of	these	patients	(III0	and	IVA0	stage	PIVC)	died	
of	 locoregional	 failure	 (2	 patients)	 and	 simultaneous	 distant	
metastasis	(1	patient).		Remaining	2	patients	with	recto-vaginal	
fistula	underwent	 surgical	 treatment;	one	of	 them	was	disease-
free	 for	 5	 years,	 the	 other	 died	 4	 years	 after	 the	 radiotherapy	
was	started	and	18	months	after	the	surgery	due	to	locoregional	
recurrence.
Cox	multifactoral	 regression	analysis	did	not	 result	 in	any	
statistically	significant,	independent	prognostic	factors	either	for	
acute	postradiation	reaction	or	late	radiotherapy	complications.	
Discussion
All	 152	 patients	 of	 the	 investigated	 group	 developed	
symptoms	 of	 postradiation	 reaction	 with	 69	 (45.4%)	 cases	 of	
considerable	intensity,	which	is	consistent	with	other	reports	[2,	
4,	22,	26-29].	
In	 some	 patients	 ineffective	 repair	 process	 is	 responsible	
for	 late	radiotherapy	complications.	In	vagina,	fibrosis,	vaginal	
narrowing	 and/or	 shortening,	 vaginal	 dryness,	 elasticity	 loss,	
ulceration	and	even	necrosis	are	observed.	Postradiation	 recto-
intestinal	 complications	 include	 persistent	 and	 bothersome	
diarrhoea,	 relapsing	 inflammations,	 chronic	 bleeding,	 and	
intestinal	and	rectal	stenosis;	complications	in	bladder	and	ureter	
include	relapsing	bladder	mucosistis,	chronic	dysuria,	hematuria	
and	ureteral	stenosis	with	progressive	hydronephrosis.
The	 most	 severe	 radiotherapy	 complications	 observed	
in	 PIVC	 patients	 include	 complete	 vaginal	 stenosis,	 vaginal	
necrosis,	 small	 bowel	 obstruction,	 intestinal	 perforation,	 and	
recto-vaginal,	vesico-vaginal	or	uretero-vaginal	fistula	[1,	2,	4-6,	
8,	9,	11,	16,	17,	19,	21,	22,	24,	25,	27,	28,	30,	31].	
As	 reported	 in	 the	 literature,	 severe	 radiotherapy	
complications	 develop	 in	 5-19%	 of	 PIVC	 patients	 [2-5,	 8-11,	
15-17,	19,	21,	24,	25,	27,	28,	30,	32].	In	the	investigated	group,	
severe	complications	occurred	in	11.8%	of	patients.
One	of	the	most	frequent	late	radiotherapy	complications	in	
PIVC	patients	 is	various	grade	vaginal	stenosis	 reported	 in	 the	
literature	 in	 10-50%	of	 the	 patients	 [2,	 22,	 33-37].	Obviously,	
much	 increased	 (G3)	vagina	narrowing	 is	 significantly	 rarer	 in	
larger	 groups,	 e.g.	 in	 55-patient	 group	 analyzed	by	Lian	et al. 
it	was	observed	in	3	cases	i.e.	in	5.5%	of	the	patients	[5].	In	the	
group	 analyzed	 in	 this	work	 vagina	 narrowing	 and	 shortening	
of	 a	 higher	 grade	 (G2a)	 had	 2	 (1.3%)	 patients	 and	 of	 a	 lower	
grade	(G1b)	additional	2	patients.	Vagina	necrosis	occurs	rarely;	
Hegemann	et al.	reported	1	case	in	a	41-patient	group,	and	Chyle	
et al.	 recorded	 8	 cases	 in	 presented	 group	 of	 301	 patients	 [4,	
11].	 Single	 necrotic	 loci	 in	 vaginal	mucosa	 are	more	 frequent	
and	reported	in	the	literature	in	4-15%	of	PIVC	patients	treated	
with	 brachytherapy	 combined	 with	 external	 radiation	 therapy	
[2,	 34,	 38].	 In	 the	 investigated	 group,	 there	 were	 no	 cases	 of	
postradiation	necrosis	in	vagina.	
Developing	 a	 fistula	 or	 fistulas	 (recto-vaginal,	 vesico-
vaginal,	 uretero-vaginal	 or	 cutaneous-vaginal)	 is	 a	 severe	
radiotherapy	 complication	 and	 its	 frequency	 is	 reported	 in	 the	
literature	as	1-8%	[5,	26,	34,	36,	39].	In	the	investigated	group	
there	were	6	cases	of	postradiation	fistula:	5	recto-vaginal	and	1	
vesico-vaginal,	which	constituted	3.9%	of	the	patients.	
	 In	the	investigated	group	there	were	3	cases	of	a	severe	
chronic	 rectal	 bleeding	 and	 3	 cases	 of	 pain	 and	 tenesmus	
associated	 with	 necrotic	 rectal	 ulceration,	 which	 constituted	
3.9%	of	patients.	Though,	there	were	no	cases	of	severe	intestinal	
complications	 requiring	 surgical	 treatment,	 i.e.	 extensive	
ulceration,	perforation	or	high	grade	stenosis,	reported	by	other	
researchers	[11,	26,	30].	
 Some	 authors	 emphasize	 the	 relation	 between	 severe	
postradiation	 complications	 occurrence	 and	 initial	 stage	 of	
neoplastic	disease;	 there	 is	no	doubt	 that	 for	 III0	and	IV0	stage	
PIVC	patients	who	were	given	radical	 radiotherapy	 the	 risk	of	
these	complications	is	much	higher	[11,	21,	26,	30,	33].	
The	 literature	 reports	 much	 more	 factors	 potentially	
increasing	late	postradiation	complication	risk	in	PIVC	patients	
such	 as	 smoking,	 earlier	 surgical	 treatment,	 inflammations	 in	
pelvic	 area,	 immunosuppression	 conditions,	 low	 body	weight,	
advanced	 age,	 accompanying	 diseases	 (diabetes,	 hypertension)	
etc.	Their	impact	has	not	been	commonly	proved,	though	it	has	
been	observed	by	some	researchers	[17,	21,	26,	30].	
Table III. Late radiotherapy complications in the group of 152 PIVC patients.
Organ
Severity (number of patients)
G1 G2 G3
Rectum - 6 5
Bladder 1 3 1
Vagina 2 3 -
Total 3 12 6
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Mock et al.	 have	 analyzed	HDR	 brachytherapy	 treatment	
administered	 alone	 or	 in	 combination	 with	 external	 radiation	
therapy	 and	 found	 no	 pre-therapeutic	 factors	 affecting	 the	
frequency	of	late	severe	postradiation	complication	occurrence,	
as	also	did	de	Crevoisier	et al.	and	authors	of	this	work	[2,	6].
Late	radiotherapy	complications	generally	develop	6	months	
to	2	years	after	the	radiation	treatment	with	the	average	of	1	year;	
more	 than	 95%	 of	 the	 complications	 occur	 within	 the	 first	 5	
years,	however,	the	complications	may	occur	even	16	years	after	
the	treatment	[29,	39].	Late	radiotherapy	complications	occurred	
in	 the	 investigated	 group	 of	 patients	 7	 to	 34	months	 after	 the	
treatment	completion	with	2/3	of	the	cases	manifesting	after	10	
to	13	months.	
Decrease	in	the	frequency	of	late	postradiation	complications	
occurrence	in	PIVC	patients	might	probably	be	achieved	by	the	
introduction	 of	 modern	 radiotherapy	 techniques,	 particularly	
IMRT	[17,	40,	41].	
Conclusions
Radiation	therapy	is	effective	and	well-tolerated	therapeutic	
management	for	PIVC	patients.	Late	radiotherapy	complications	
occur	in	several	per	cent	of	the	cases,	and	severe	complications,	
mainly	of	grade	3,	only	in	few	per	cent	of	the	patients.	Providing	
appropriate	 conservative	 or	 surgical	 treatment	 (fistulas),	 the	
complications	are	not	life-threatening	for	the	patients.	
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